| FTNT |
Report |
Total revenue |
BEAT |
pred ~$1.910B vs. cons $1.888B |
MEDIUM |
| FTNT |
Report |
Total billings |
BEAT |
pred ~$2.170B vs. cons $2.142B |
MEDIUM |
| FTNT |
Report |
Non-GAAP diluted EPS |
BEAT |
pred ~$0.77 vs. cons $0.75 |
MEDIUM |
| FTNT |
Guide |
Q3 revenue |
BETTER |
guide midpoint ~$1.97B vs. cons $1.949B |
MEDIUM |
| FTNT |
Guide |
Q3 billings |
BETTER |
guide midpoint ~$2.12B vs. cons $2.082B |
MEDIUM |
| FTNT |
Guide |
FY26 revenue |
BETTER |
guide midpoint ~$7.97B vs. cons $7.804B |
MEDIUM |
| FTNT |
Guide |
FY26 billings |
BETTER |
guide midpoint ~$9.13B vs. cons $8.942B |
MEDIUM |
| FTNT |
Guide |
H2 service-revenue commentary |
BETTER |
reaffirmed acceleration with higher confidence |
MEDIUM |
| FTNT |
Return |
Day-1 residual (stock − beta × S&P 500) |
+7.0% |
— |
LOW |
| FTNT |
Return |
5-day cumulative residual |
+10.0% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — stronger out-period guide should drive revisions |
LOW |